logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Q

Qingshu Zeng

hematology
H指数:12
被引数:1,133

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial

Penpulimab联合来那度胺和r-gemox方案 (R2-GemOx-PD1i) 治疗复发或难治性弥漫性大b细胞淋巴瘤: 一项多中心，单臂，2期试验

BMC Medicine
IF8.3
2026-02-090
OAAI
Jin-Hua Liang; Tong-Yao Xing; Wei-Ying Gu; Hua Yin; Qing-Shu Zeng; Kai-Xin Du; Luthuli Sibusiso; Jia-Zhu Wu; Yue Li; Fei Wang; Rui Gao; Jian-Yong Li; Hao-Rui Shen; Li Wang; Wei Xu
Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities

更正：维奈克拉联合去甲基化药物用于急性髓系白血病诱导治疗的疗效及预后分析：一项针对适应症特定分层、分子标志物和血液学毒性的多中心真实世界研究

Cancer Cell International
IF6
2025-10-290
OAAI
Leiming Xia; Mengni Qu; Ling Ge; Yingying Chen; Beibei Zhou; Ting Shi; Yang Liu; Min Ruan; Liang Xia; Jian Hong; Jianjun Li; Wei Qian; Yu Zhang; Lei Jiang; Yiming Zhao; Wanlu Tian; Zhenqi Huang; Fengbo Jin; Jian Ge; Mingzhen Yang; Qingshu Zeng
Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Ponatinib 2年疗效、安全性和健康相关生活质量：中国一项开放标签、多中心、II期临床试验，用于费城染色体阳性白血病患者

BLOOD
IF23.1
2024-11-050
PRE
Yu, Lu; Wang, Huifang; Liu, Xiaoli; Liu, Bingcheng; Zhao, Xielan; He, Qun; Zeng, Qingshu; Sun, Zimin; Liu, Ting; Zhu, Huanling; Liu, Zhuogang; Du, Xin; Jin, Jie; Meng, Li; Hou, Ming; Chen, Suning; Yang, Linhua; Xian, Mingji; Kotobuki, Yoshitaka; Zhang, Shuang; Jiang, Qian
Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

每周 Selinexor、Bortizomib 和 Dexamethasone (SVd) 与每周两次 Bortizomib 和 Dexamethasone (Vd) 在中国复发性和难治性多发性骨髓瘤 (RRMM) 患者中的比较：Bench 研究的初步分析

BLOOD
IF23.1
2024-11-050
PRE
Lu, Jin; Geng, Liangquan; Chen, Lijuan; Liu, Peng; Zhong, Yuping; Liu, Zhuogang; Xia, Zhongjun; Mi, Jianqing; Li, Chunrui; Zhang, Xi; He, Yanjuan; Wei, Yongqiang; Fang, Baijun; Li, Fei; Cai, Zhen; Wang, Yafei; Huang, Dongping; Liu, Hong; Hou, Ming; Fu, Rong; Du, Xin; Fang, Xiaosheng; Zeng, Qingshu; Gao, Wen; Wang, Wei; Chang, Chunkang; Ouyang, Guifang; Liu, Jing; Weng, Jianyu; Huang, Xiaobing; Yu, Yang; Guo, Zhi; Zhao, Jun; Hou, Jian
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

sovleplenib (HMPL-523) 在中国 (ESLIM-01) 成人慢性原发性免疫性血小板减少症患者中的疗效和安全性: 一项随机，双盲，安慰剂对照的3期研究

LANCET HAEMATOLOGY
IF17.7
2024-08-013
PRE
Hu, Yu; Liu, Xiaofan; Zhou, Hu; Wang, Shujie; Huang, Ruibin; Wang, Yi; Du, Xin; Sun, Jing; Zhou, Zeping; Yan, Zhenyu; Chen, Wenming; Wang, Wei; Liu, Qingchi; Zeng, Qingshu; Gong, Yuping; Yin, Jie; Shen, Xuliang; Ye, Baodong; Chen, Yun; Xu, Yajing; Sun, Huiping; Cheng, Yunfeng; Liu, Zhuogang; Wang, Chunling; Yuan, Guolin; Zhang, Xiaohui; Li, Xin; Cheng, Peng; Guo, Xinhong; Jiang, Zhongxing; Yang, Feng'e; Yang, Linhua; Luo, Chengwei; Xiao, Taiwu; Fu, Sisi; Yin, Hongyan; Guo, Xiaojun; Xu, Qian; Fan, Songhua; Shi, Michael M.; Su, Weiguo; Mei, Heng; Yang, Renchi
TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes

AML母细胞的TIM-3表达水平与核心结合因子易位的存在相关，而不是临床结果

FRONTIERS IN ONCOLOGY
IF3.3
2022-04-144
OAAI
Hong, Jian; Xia, Leiming; Huang, Zhenqi; Yuan, Xiaodong; Liang, Xinglin; Dai, Jifei; Wu, Zhonghui; Liang, Li; Ruan, Min; Long, Zhangbiao; Cheng, Xin; Chen, Xiaowen; Ni, Jing; Ge, Jian; Li, Qingsheng; Zeng, Qingshu; Xia, Ruixiang; Wang, Yi; Yang, Mingzhen
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
FRONTIERS IN ONCOLOGY
IF3.3
2021-11-0420
OAAI
Liu, Weiping; Zhao, Donglu; Liu, Ting; Niu, Ting; Song, Yongping; Xu, Wei; Jin, Jie; Cai, Qingqing; Huang, Huiqiang; Li, Zhiming; Hou, Ming; Zhang, Huilai; Zhou, Jianfeng; Hu, Jianda; Shen, Jianzhen; Shi, Yuankai; Yang, Yu; Zhang, Liling; Zhao, Weili; Ding, Kaiyang; Qiu, Lugui; Tan, Huo; Zhang, Zhihui; Liu, Lihong; Wang, Jinghua; Xu, Bing; Zhou, Hui; Gao, Guangxun; Xue, Hongwei; Bai, Ou; Feng, Ru; Huang, Xiaobing; Yang, Haiyan; Yan, Xiaojing; Zeng, Qingshu; Liu, Peng; Li, Wenyu; Mao, Min; Su, Hang; Wang, Xin; Xu, Jingyan; Zhou, Daobin; Zhang, Hongyu; Ma, Jun; Shen, Zhixiang; Zhu, Jun
High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial
AMERICAN JOURNAL OF HEMATOLOGY
IF9.9
2020-10-1941
OAAI
Yu, Yafei; Wang, Miaomiao; Hou, Yu; Qin, Ping; Zeng, Qingshu; Yu, Wenzheng; Guo, Xinhong; Wang, Jingxia; Wang, Xiaomin; Liu, Guoqiang; Chu, Xiaoxia; Yang, Lan; Feng, Ying; Zhou, Fang; Sun, Zhaogang; Zhang, Mei; Wang, Xin; Wang, Zhencheng; Ran, Xuehong; Zhao, Hongguo; Wang, Lei; Zhang, Haiyan; Bi, Kehong; Li, Daqi; Yuan, Chenglu; Xu, Ruirong; Wang, Yili; Zhou, Yuhong; Peng, Jun; Liu, Xin-guang; Hou, Ming
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
LANCET HAEMATOLOGY
IF17.7
2019-06-0133
PREAI
Xu, Peng-Peng; Fu, Di; Li, Jian-Yong; Hu, Jian-Da; Wang, Xin; Zhou, Jian-Feng; Yu, Hao; Zhao, Xia; Huang, Yao-Hui; Jiang, Lu; Liu, Feng; Su, Li-Ping; Chen, Zhuo-Wen; Zeng, Qing-Shu; Chen, Jie-Ping; Fang, Mei-Yun; Ma, Jun; Liu, Ting; Song, Yong-Ping; Yu, Kang; Li, Yan; Qiu, Lu-Gui; Chen, Xie-Qun; Gu, Jian; Yon, Jin-Song; Hou, Ming; Huang, Heng-Ye; Wang, Li; Cheng, Shu; Shen, Yang; Xiang, Hui; Chen, Sai-Juan; Zhao, Wei-Li
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
JOURNAL OF HEMATOLOGY & ONCOLOGY
IF40.4
2017-03-15200
OAAI
Shi, Yuankai; Jia, Bo; Xu, Wei; Li, Wenyu; Liu, Ting; Liu, Peng; Zhao, Weili; Zhang, Huilai; Sun, Xiuhua; Yang, Haiyan; Zhang, Xi; Jin, Jie; Jin, Zhengming; Li, Zhiming; Qiu, Lugui; Dong, Mei; Huang, Xiaobing; Luo, Yi; Wang, Xiaodong; Wang, Xin; Wu, Jianqiu; Xu, Jingyan; Yi, Pingyong; Zhou, Jianfeng; He, Hongming; Liu, Lin; Shen, Jianzhen; Tang, Xiaoqiong; Wang, Jinghua; Yang, Jianmin; Zeng, Qingshu; Zhang, Zhihui; Cai, Zhen; Chen, Xiequn; Ding, Kaiyang; Hou, Ming; Huang, Huiqiang; Li, Xiaoling; Liang, Rong; Liu, Qifa; Song, Yuqin; Su, Hang; Gao, Yuhuan; Liu, Lihong; Luo, Jianmin; Su, Liping; Sun, Zimin; Tan, Huo; Wang, Huaqing; Wang, Jingwen; Wang, Shuye; Zhang, Hongyu; Zhang, Xiaohong; Zhou, Daobin; Bai, Ou; Wu, Gang; Zhang, Liling; Zhang, Yizhuo

研究方向

暂未获取到该数据
M
Ming Hou
H 指数:50论文数:398被引数:9,695
王鑫 封面图
王鑫
H 指数:88论文数:1,766被引数:3.7万
刘婷 封面图
刘婷
H 指数:81论文数:1,795被引数:4.0万
H
Heyu Ni
H 指数:60论文数:292被引数:1.0万
J
Jun Peng
H 指数:45论文数:231被引数:6,594
X
Xiaobing Huang
H 指数:23论文数:161被引数:2,265
J
Jianfeng Zhou
H 指数:63论文数:591被引数:1.6万
L
Lili Tao
H 指数:27论文数:158被引数:3,162
阮
阮敏
H 指数:20论文数:98被引数:1,442
J
Jie Jin
H 指数:28论文数:175被引数:2,603